Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Immunisation, Shigella Infection
Interventions: Placebo, Shigella sonnei strain 53G, WRSs2; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Decatur, Georgia • Cincinnati, Ohio

Conditions: Wound Heal
Interventions: Free Gingival Graft Procedure; Procedure
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Posterolateral Thoracotomy, Postoperative Pain
Interventions: EXPAREL 266 mg, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Miami, Florida • Shreveport, Louisiana • Fargo, North Dakota + 4 more

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Blood Loss During Vaginal Hysterectomy
Interventions: Vasopressin; Drug
Lead sponsor: Ascher-Walsh, Charles, M.D.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Laparoscopic Appendectomy
Interventions: Bupivacaine, Placebos; Drug
Lead sponsor: Metro Health, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: COVID -19, COVID-19 (Prevention)
Interventions: MDX2301, Normal Saline; Biological
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Postpartum Hemorrhage
Interventions: Tranexamic Acid, Placebo; Normal Saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prematurity, Apnea, Respiratory Failure
Interventions: Caffeine citrate, Normal saline; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 1 Day to 5 Days
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Delayed Graft Function
Interventions: BB3; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: San Diego, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more

Conditions: Interstitial Cystitis
Interventions: LP-08 80mg, Normal saline, LP-08 20mg; Drug
Lead sponsor: Lipella Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Anesthesia, Pain, Surgery
Interventions: Saline, Ketamine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis Thumb
Interventions: Platelet Concentrate, Corticosteroid injection, Normal Saline; Drug · Other
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Centerville, Ohio

Conditions: Hip Fractures
Interventions: Tranexamic Acid Injectable Solution, Placebo; Drug · Other
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Obesity
Interventions: intravenous acetaminophen, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Fluzone HD; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 34
States / cities: Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more

Conditions: Overactive Bladder
Interventions: botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U); Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Middlebury, Connecticut

Conditions: Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions: Inhaled Prostaglandin E1; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 7 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 11
States / cities: Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more

Conditions: Nonallergic Irritant Rhinitis
Interventions: Capsaicin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Blood Loss Anemia, Fracture
Interventions: Iron-Dextran Complex Injection [InFed], Saline Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more

Conditions: Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Phase 2 Shigella Vaccine and Challenge

Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial

A Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

Tranexamic Acid and Thromboelastography During Cesarean Delivery

Caffeine to Reduce Mechanical Ventilation in Preterm Infants

Study to Improve Renal Function After Kidney Transplantation

Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion

Single Blinded First CMC Osteoarthritis Treatment

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

Prospective, Double Blind, Placebo Control, Bariatric IV Ace

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Budesonide Inhalation Suspension for Acute Asthma in Children